174 related articles for article (PubMed ID: 37612635)
1. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
4. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
[TBL] [Abstract][Full Text] [Related]
5. Evolving management of early stage pancreatic adenocarcinoma in older patients.
Nassoiy S; Christopher W; Marcus R; Keller J; Weiss J; Chang SC; Essner R; Foshag L; Fischer T; Goldfarb M
Am J Surg; 2023 Jan; 225(1):212-219. PubMed ID: 36058752
[TBL] [Abstract][Full Text] [Related]
6. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
[TBL] [Abstract][Full Text] [Related]
7. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
[TBL] [Abstract][Full Text] [Related]
8. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
9. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma.
da Costa WL; Tran Cao HS; Gu X; Massarweh NN
Ann Surg; 2022 Mar; 275(3):415-421. PubMed ID: 35120060
[TBL] [Abstract][Full Text] [Related]
10. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
[TBL] [Abstract][Full Text] [Related]
11. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
12. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
[TBL] [Abstract][Full Text] [Related]
14. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
15. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
[TBL] [Abstract][Full Text] [Related]
16. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
Chen YT; Huang ZP; Zhou ZW; He MM
Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
[TBL] [Abstract][Full Text] [Related]
17. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
[TBL] [Abstract][Full Text] [Related]
19. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
[TBL] [Abstract][Full Text] [Related]
20. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]